The mission of the Analytical Biochemistry (AB) Shared Resource is to provide high-quality analytical capabilities to members of the Masonic Cancer Center (MCC). The Resource offers access to state-of-the-art instrumentation and advanced mass spectrometric analyses in a timely and cost-efficient manner, and guides MCC members on sample preparation, instrumentation usage, and analytical rigor through extensive training. The Resource provides bioanalytical and mass spectrometric tools to research activities of the MCC Programs, in particular, the Carcinogenesis and Chemoprevention (CC) and the Screening Prevention Etiology Cancer Survivorship (SPECS) Programs. These services and expertise are critical for the mission of the MCC because they assess exposure to and the biological effects of carcinogens, which are crucial to understanding both risk and risk mitigation. The researchers who use the Resource have made great strides in measuring biomarkers of human exposures to carcinogenic substances and the resulting DNA damage. Major ongoing research efforts that utilize the Resource include 1) Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking implements biomarkers to identify racial and ethnic differences in susceptibility to lung cancer; 2) the NIEHS-sponsored Children's Health Exposure Analyses Resource is advancing knowledge of environmental exposures that may impact children's health; 3) Role of cooked meat mutagens and DNA adduct formation in prostate cancer and 4) NIH- and FDA-sponsored cooperative agreements (U54DA031659, PIs E Donny [U Pitt] and D. Hatsukami), which include large clinical trials evaluating the efficacy of reduced nicotine cigarettes in decreasing cigarette smoking (PI: Hatsukami). Over the past 5 years, the Resource has provided essential mass spectrometry support for the research of 32 PIs of 39 NIH-funded grants addressing many programs in cancer, chemoprevention, and public health. The AB Shared Resource is led by Dr. Robert Turesky, who oversees coordinators for mass spectrometry services (Dr. Peter Villalta), AB services (Dr. Sharon Murphy), and chromatography services (Mr. Steven Carmella). Dr. Turesky replaced Dr. Stephen Hecht as the Director in 2013. Dr. Turesky has 30 years of experience in using bioanalytical mass spectrometry to characterize and measure biomarkers of dietary carcinogens. Dr. Villalta's role and responsibilities have also changed since he received an NCI R50 Research Specialist Award in 2016. He now dedicates 43% of his efforts to coordinating the mass spectrometry services, and 57% effort to providing advanced mass spectrometric analytical capabilities to members of the CC Program. Mr. Xun Ming, who manages the Mass Spectrometry Laboratory, was recruited in 2014, Yingchun Zhao, PhD, an analytical chemist with a proteomics background, was recruited in 2015, and Makenzie Pillsbury, BS, who previously worked for Dr. Hecht and has experience in LC/MS and GC/MS, was hired in 2017. All offer support services within the Mass Spectrometry Laboratory.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-23
Application #
10086430
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
23
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Scott, Milcah C; Temiz, Nuri A; Sarver, Anne E et al. (2018) Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. Cancer Res 78:326-337
Guo, Zhijun; Johnson, Veronica; Barrera, Jaime et al. (2018) Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev 37:409-423
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Ho, Yen-Yi; Nhu Vo, Tien; Chu, Haitao et al. (2018) A Bayesian hierarchical model for demand curve analysis. Stat Methods Med Res 27:2038-2049
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383
Kaizer, Alexander M; Hobbs, Brian P; Koopmeiners, Joseph S (2018) A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. Biometrics 74:1082-1094
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Sperduto, Paul W; Deegan, Brian J; Li, Jing et al. (2018) Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 20:1652-1660
Li, Danni; Huang, Fangying; Zhao, Yingchun et al. (2018) Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study. Clin Proteomics 15:31

Showing the most recent 10 out of 1013 publications